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Background: In the BREATHE trial weekly azithromycin decreased the rate of acute respiratory exacerbations
(AREs) compared to placebo among children and adolescents with HIV-associated chronic lung disease (CLD)
taking antiretroviral therapy (ART). The aim of this analysis was to identify risk factors associated with AREs
and mediators of the effect of azithromycin on AREs.
Methods: The primary outcome of this analysis was the rate of AREs by study arm up to 49 weeks. We ana-
lysed rates using Poisson regression with random intercepts. Interaction terms were fitted for potential effect
modifiers. Participants were recruited from Zimbabwe and Malawi between15 June 2016 and 4 September
2018.
Findings: We analysed data from 345 participants (171 allocated to azithromycin and 174 allocated to pla-
cebo). Rates of AREs were higher among those with an abnormally high respiratory rate at baseline (adjusted
rate ratio (aRR) 2.08 95% CI 1.10-3.95 p-value 0.02) and among those with a CD4 cell count <200 cells/mm3
(aRR 2.71; 95% CI 1.27-5.76; p-value 0.008). We found some evidence for variation in the effect of azithromy-
cin by sex (p-value for interaction=0.07); males had a greater reduction in the rate of ARE with azithromycin
treatment than females. We found that azithromycin had a greater impact on reducing AREs in participants
with chronic respiratory symptoms at baseline, those on 1st line ART, with a FEV1 score >-2 and participants
without baseline resistance to azithromycin. However, there was no statistical evidence for interaction due
to low statistical power.
Interpretation: These may represent subgroups who may benefit the most from treatment with weekly azi-
thromycin, which could help guide targeted treatment.
Funding: There was no funding source for this post hoc analysis.
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)nical Research, London School
Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)1. Introduction
The scale-up of paediatric antiretroviral therapy (ART) has
resulted in a dramatic increase in survival such that children who
would have died in infancy or early childhood are now surviving toadolescence. However, children and adolescents growing up with
HIV experience a range of multisystem comorbidities despite ART,
which may be sequelae of infections that occur as a result of immu-
nosuppression caused by HIV or a consequence of HIV infection itself
or its treatment. Chronic lung disease (CLD) is one of the most com-
mon comorbidities among older children and adolescents with HIV
[1]. In the pre-ART era, lymphoid interstitial pneumonitis (LIP) was
the most common cause of CLD. LIP responds well to ART and is now
a rare presentation to clinical practice [2]. Recent studies from sub-
Research in context
Evidence before this study
At present little evidence exists on the management of chronic
lung disease (CLD) in children and adolescents with HIV. We
conducted a literature review of the clinical, lung function and
radiological features of CLD in children and adolescents with
Human immunodeficiency virus (HIV). We identified 17 stud-
ies, 16 observational and one randomised, placebo controlled
trial which investigated the effect of prophylactic erythromycin
on respiratory exacerbations in children with HIV-related bron-
chiectasis. This study found no difference in exacerbations
between the treatment and placebo group, but only included
31 participants. Azithromycin has both anti-microbial and anti-
inflammatory activity, which may help to suppress immune
activation and provide prophylaxis against respiratory infec-
tions. In patients with cystic fibrosis, treatment with azithro-
mycin resulted in improved lung function, reduced respiratory
exacerbations and a reduced need for treatment with oral anti-
biotics. The BREATHE trial found that treatment with weekly
azithromycin for 48 weeks did not result in improved lung
function but did significantly lower the risk of acute respiratory
exacerbations.
Added value of this study
In this post hoc analysis of the BREATHE trial we examined risk
factors for acute respiratory exacerbations (AREs), and factors
that modify the association between weekly azithromycin and
risk of AREs. We found that a baseline abnormally high respira-
tory rate and CD4 count <200 cells/mm3 were associated with
a higher risk of AREs. We found evidence that azithromycin
was more effective at reducing AREs in male participants and in
participants with chronic respiratory symptoms, an FEV1 Z-
score -2, those on 1st line ART, and without resistance to azi-
thromycin at baseline, although we were underpowered to
detect statistical evidence for interaction in effects.
Implications of all the available evidence
These may represent subgroups who may benefit the most
from treatment with weekly azithromycin. The use of targeted
treatment may reduce concerns regarding antimicrobial resis-
tance (AMR). Further studies to evaluate the sustainability of
effect, the optimum dose and length of treatment are needed.
These studies should also evaluate the risk of AMR and the
cost-benefit of treatment.
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chiolitis is now the predominant underlying cause for CLD in children
and adolescents with HIV, and is associated with morbidity including
chronic cough, hypoxia, reduced exercise tolerance and recurrent
respiratory tract infections [1,3].
The BREATHE (Bronchopulmonary function in response to azi-
thromycin treatment for chronic lung disease in HIV-infected chil-
dren) trial investigated whether adjuvant treatment with weekly
azithromycin (AZM) for 48 weeks results in improved lung function
in children and adolescents aged 6-19 years with HIV taking ART
who had CLD [4]. Azithromycin did not lead to a significant improve-
ment in forced expiratory volume in 1 second (FEV1) Z-score (pri-
mary outcome), but did lead to a significant reduction in the risk of
acute respiratory exacerbations (AREs) (secondary outcome) [5].
Respiratory infections have been shown to be the most common
cause of hospital admissions amongst adolescents with HIVestablished on ART, and AREs are likely to impact significantly on
morbidity and quality of life [6].
In this post hoc analysis of the BREATHE trial, we investigated the
effect of azithromycin on AREs to identify potential subgroups who
would most benefit from azithromycin treatment. Specifically, we
investigated the risk factors for AREs in both the placebo and azithro-
mycin group; crude rates of AREs and factors that may modify the
effect of azithromycin on risk of AREs.
2. Methods
2.1. Study Design
The BREATHE trial is a multicentre, individually randomised, pla-
cebo-controlled trial. A detailed study protocol has been published
[4].
Participants were recruited from outpatient HIV clinics at the Har-
are Childrens Hospital (Zimbabwe) and Queen Elizabeth Central Hos-
pital in Blantyre (Malawi). For those aged <18 years consent was
sought from the guardian with age-appropriate assent from the par-
ticipant, whilst those aged18 years consented independently.
Ethical approval was provided by College of Medicine Research
Ethics Committee (COMREC) (Malawi), the Medical Research Council
of Zimbabwe and the Biomedical Research and Training Institute IRB
(Zimbabwe), the London School of Hygiene and Tropical Medicine
Ethics Committee (UK) and the University of Tromso Ethics Commit-
tee (Norway). The trial is registered with ClinicalTrials.gov,
NCT02426112. This secondary analysis was conducted in adherence
with the STROBE guidelines.
2.2. Participants
Participants were eligible if they were aged 6-19 years, had been
on any combination of ART for at least six months and had CLD,
defined as an FEV1 Z-score less than -1.0 with no reversibility (<12%
improvement in FEV1 after 200mcg of salbutamol inhaled via a
spacer), established by spirometry. Exclusion criteria included having
a potentially fatal condition, tuberculosis (TB) or an acute respiratory
infection (ARI) at the time of screening, pregnancy, breastfeeding,
history of a cardiac arrythmia, a prolonged QTc interval (>440 milli-
seconds in males and >460 milliseconds females), creatinine clear-
ance <30 mls/minute, elevated alanine aminotransferase (ALT)
>2 times the upper limit of normal, known hypersensitivity to a mac-
rolide and concomitant use of drugs known to cause QTc prolonga-
tion. TB screening was performed using the XpertTM MTB/RIF
(Cepheid, Sunnyvale, CA, USA) on one sputum sample obtained either
spontaneously or through induction. Participants over 18 consented
independently. For those aged <18 consent was sought from the
guardian with age-appropriate assent from the participant.
2.3. Randomisation and Masking
Participants were randomised 1:1 by block randomisation to
receive either an oral weekly weight-based dose of azithromycin or
placebo. An independent statistician who had no involvement with
the trial generated the randomisation schedule and allocation list
using Stata version 14.0 (StatCorp, Texas, USA). Randomisation was
performed with block sizes between two to six participants and was
stratified by country. Participants and data collectors and outcome
assessors were blinded to group allocation. The allocation list was
sent directly to the study pharmacists, who prepared the study medi-
cation. The pharmacists were blind to treatment allocation but
unblinded to group allocation as they were provided with allocations
for study numbers into trial arm 1 or 2, and matched this to study
medication labelled trial arm 1 or 2.
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Weight-based oral azithromycin tablets (1019.9 kg, 250 mg;
2029.9 kg, 500 mg; 3039.9 kg, 750 mg; > 40 kg, 1250 mg) or iden-
tical placebo tablets were given weekly under direct observation by a
treatment monitor identified within the family for a total of 48
weeks. Characteristics recorded at baseline include socio-demo-
graphic and clinical history, symptom history, drug history, spirome-
try, shuttle walk test, height, weight, electrocardiogram (ECG), serum
creatinine and ALT, pregnancy test, sputum sample for TB screening,
CD4 count, HIV viral load (VL). Participants were followed up at two
weeks and at three monthly intervals thereafter for a total of 49
weeks. Participants were asked to attend for an unscheduled visit if
they developed acute symptoms. AREs were defined as new or wors-
ening respiratory symptoms (cough with or without sputum produc-
tion, breathlessness, chest pain) with or without fever as assessed by
a clinician. For participants attending with AREs, sputum and nasal
swabs were taken and participants were treated with co-amoxiclav
for 10 days. If this resulted in no improvement than a CXR and culture
for Mycobacterium tuberculosis (M. tb) was performed. Participants
were also asked to contact the study team if they were admitted to
hospital, and were asked about hospitalisation at each study visit.
Detailed microbiological procedures and results have been
reported previously [7,8]. Conventional culture was performed for
common bacterial pathogens at baseline, 12 and 18 months on spu-
tum and nasopharyngeal samples. Antibiotic susceptibility testing
was performed on relevant cultured isolates using Vitek-2 (bioMer-
ieux, France) or disk diffusion testing
2.5. Statistical Analysis
Statistical analysis was performed using STATA software version
16.1 (STATA Corp, College Station, Texas, USA). The pre-specified
analysis of the BREATHE trial has been described elsewhere [4,5]. In
this post-hoc analysis, incidence rate ratios (IRR) of AREs by arm with
95% confidence intervals (CIs) were calculated. Poisson regression
was used to create a model of the effect of azithromycin on AREs,
with random effects to account for multiple events within a partici-
pant. Lexis expansion was used to allow for joint adjustment of time
variables (including season, calendar time and follow-up time), to
look for variation of rates of AREs within these. Season was defined
as rainy (November to April) and dry (May to October); calendar time
was split into two groups, 2016-2017 versus 2018-2019; and follow-
up time was split into four 12-week periods corresponding to the
prescribing regimen. The relationship between ARE and time varia-
bles independent of other risk factors was explored. Collinearity
among time variables was assessed by examining the change in stan-
dard errors between unadjusted and models adjusted for other time
variables. All subsequent models were adjusted for those time varia-
bles which had Wald p-value <0.1 once adjusted for each other and
where they did not exhibit co-linearity. Participants were censored at
death, last study visit if lost to follow-up, date of withdrawal if with-
drawn from the study or at 49 weeks after commencing study medi-
cation. Two participants missing HIV VL at baseline were excluded
from all analyses.
Risk factors for AREs were examined among participants in both
the azithromycin and placebo groups. Risk factors at enrolment
included FEV1 Z-score, CD4 cell count, being on 2nd line ART, weight-
for- age Z-score, height-for-age Z-score [9], presence of current
cough, tachypnoea (defined as a respiratory rate greater than the
99th percentile of age-specific values) [10] and a history of treatment
for TB. An adjusted model included trial arm, age group, sex, site and
HIV VL at enrolment, in alignment with the primary analysis, as the
latter characteristics were found to differ between trial arms by
chance and were also associated with loss to follow-up [5]. The model
estimates therefore accounted for missing data under a missing atrandom assumption. A second model was created which included the
above mentioned characteristics as well as additional variables that
were found to be associated with AREs in the initial model (p-value
<0.1) (model 2).
Data from both trial arms was used to explore whether the
reduced rate of AREs among those receiving azithromycin treatment,
a pre-specified secondary outcome of the trial reported elsewhere
[5], exhibited heterogeneity in effect by any of the risk factors
assessed for their association with ARE. Adjusted random effects Pois-
son regression models were used to explore whether the effect of azi-
thromycin on AREs was modified by baseline risk factors including
age group, sex, FEV1 Z-score, CD4 cell count, HIV VL, history of treat-
ment for TB, weight-for-age Z-score, height-for-age Z-score, presence
of cough and tachypnoea, and additionally carriage of azithromycin-
resistant bacteria (in sputum or from nasal swab), and time variables
(season, calendar time and time in study). P-values for interaction
were determined using a likelihood ratio test (LRT) and indicated the
strength of evidence that the treatment effect of azithromycin versus
placebo was heterogeneous between risk factor levels. Age was
regrouped in the interaction term into two levels (6-15 and 16+) but
adjusted as three levels in other models (6-10, 11-15 and 16). Viral
load was adjusted for as a continuous variable but included in the
interaction term as two levels, supressed (<1000 copies/ml) or
unsuppressed (1000 copies/ml). Models were adjusted for a priori
factors as per the primary analysis and time variables as previously
stated. For risk factors where heterogeneity between the stratum
specific estimates was observed unadjusted cumulative event curves,
stratified by risk factor level and trial arm were generated. As AREs
can occur multiple times in the same individual, so that individuals
remain at risk of another ARE after they have recovered, participants
who experienced an ARE were retained in the at-risk group and not
censored unless they were lost to follow-up or died.
2.6. Role of the Funding Source
The BREATHE trial was funded by the GLOBVAC Programme of the
Medical Research Council of Norway. The funder had no role in study
design, data collection, data analysis, data interpretation or manu-
script writing. There was no funding source for this post hoc analysis.
3. Results
Participants were recruited between 15 June 2016 and 4 Septem-
ber 2018 and follow up ended in August 2019. Of the 347 participants
included in the BREATHE trial, 345 participants had no missing infor-
mation for all variables of interest and were included in this analysis,
with 171 participants randomised to the azithromycin and arm and
174 participants randomised to the placebo arm. Baseline character-
istic of participants stratified by trial arm and outcome (at least one
ARE episode) are summarised in Table 1. In both trial arms, those
who experienced at least one ARE were older, had lower FEV1 Z-score
at baseline, had a lower CD4 cell count, higher HIV VL, and com-
menced ART at older age.
In the azithromycin arm, more females developed at least one ARE
compared to males (68.8% vs 31.2%), but this was not the case in the
placebo arm where a similar proportion of females and males devel-
oped at least one ARE (46.7% vs 53.3% respectively). Participants who
in the azithromycin arm experienced at least one ARE were more
malnourished than those in the placebo arm who experienced at
least one ARE. Overall, 9.0% of participants had a cough at baseline;
however, 26.7% of the participants in the placebo group who devel-
oped an ARE had a cough at baseline. An abnormal respiratory rate at
baseline was observed in almost half of participants (43.8%), and this
subgroup was also overrepresented in those who developed one or
more AREs in the placebo arm, with 70.0% of these participants hav-
ing an abnormal respiratory rate at baseline (Table 1).
Table 1
Baseline characteristics of participants by trial arm and whether they experienced at least one ARE.
All participants Azithromycin (AZM) arm Placebo arm
No ARE At least one ARE No ARE At least one ARE
Total, n (%) 345 155 (90.6) 16 (9.4) 144 (82.8) 30 (17.2)
Median (IQR) age in years 15.3 (12.7-17.7) 14.7 (12.2-16.9) 15.2 (14.2-17.0) 15.1 (13.0-18.10) 16.1 (12.7-18.6)
Female sex, n (%) 168 (48.7) 67 (85.9) 11 (14.1) 76 (84.4) 14 (15.6)
Site: Zimbabwe, n (%) 241 (69.9) 106 (88.3) 14 (11.7) 95 (78.5) 26 (21.5)
Mean FEV1 Z-score at enrolment (SD) -2.0 (0.8) -2.0 (0.7) -2.4 (0.8) -1.9 (0.7) -2.3 (1.0)
Mean FEV1 in litres at enrolment (SD) 1.7 (0.5) 1.6 (0.5) 1.5 (0.3) 1.7 (0.5) 1.7 (0.6)
Mean FVC Z-score (SD) -1.7(0.9) -1.8 (1.0) -2.0 (1.0) -1.6 (0.78) -2.1(1.2)
Mean FVC in litres (SD) 2.0(0.6) 2.0 (0.6) 1.8 (0.4) 2.0 (0.6) 2.1(0.7)
Mean FEV1/FVC ratio Z-score (SD) -0.7 (1.1) -0.7(1.13) -1.1 (1.1) -0.7 (1.1) -0.8 (1.3)
Mean FEV1/FVC ratio (SD) 0.8 (0.8) 0.9 (0.8) 0.8 (0.8) 0.8 (0.1) 0.8 (0.1)
Median (IQR) CD4 count cells/mm3 572 (356-784) 611 (418-788) 566.5 (360.5-856) 561.5 (343-807.5) 456 (248-659)
Median (IQR) HIV VL copies/ml 400 (39-13200) 309 (39-17700) 398 (59.5-2200) 286.5 (42-11180) 1835 (400-52700)
No (%) with HIV VL <1000 copies/ml 194 (56.2) 91 (91.0) 9 (9.0) 81 (86.2) 13 (13.8)




















No (%) on second line ART regimen 87 (25.5) 38 (82.6) 8 (17.4) 31 (75.6) 10 (24.4)
Mean (SD) weight-for-age Z-score -2.2 (1.5) -2.2 (1.4) -2.3 (1.5) -2.1 (1.5) -2.2 (1.3)
No (%) underweight 180 (52.2) 87 (89.7) 10 (10.3) 68 (81.9) 15 (18.1)
Mean (SD) height-for-age Z-score -2.1 (1.2) -2.1 (1.2) -2.4 (1.1) -2.1 (1.3) -1.9 (1.1)
No (%) stunted 174 (50.4) 84 (89.4) 10 (10.6) 67 (83.8) 13 (16.3)
No (%) with history of treatment for TB 97 (28.2) 50 (86.2) 8 (13.8) 30 (76.9) 9 (23.1)
No (%) admitted for chest problems in the past 12 months 6 (1.73) 2 (100.0) 0 (0) 1 (33.3) 2 (66.7)
No (%) with cough 31 (9.0) 12 (92.3) 1 (7.7) 10 (55.6) 8 (44.4)
Mean (SD) respiratory rate 22.4 (3.1) 22.1 (3.0) 23.2 (3.4) 22.5 (3.3) 23 (3.0)
No (%) with abnormal RR 151 (43.8) 59 (89.4) 7 (10.6) 64 (75.3) 21 (24.7)
No (%) with resistance to AZM 34 (9.9) 12 (85.7) 2 (14.3) 18 (90.0) 2 (10.0)
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pants and 19 total episodes of AREs in the azithromycin arm, over a
total of 154 and 157 person years respectively. In the azithromycin
arm 14 participants had 1 ARE, 1 had 2 AREs and 1 had 3. In the pla-
cebo arm 24 participants had 1 ARE, 4 had 2 AREs and 2 had 3. In total
37 out of 57 AREs (64.9%) were treated with antibiotics. There was
evidence that the rate of AREs varied by season, calendar period and
time in study in an unadjusted analysis (Tables S1 and S2). After
adjusting for each other, season and calendar period remained associ-
ated with the rate of AREs both in the placebo arm (Wald p-
value=0.04 and p=0.05 respectively) and in the azithromycin arm
(Wald p-value= 0.04 and p=0.01). Rates of ARE were lower in the
rainy season compared to the dry season and reduced over time
(lower in 2018-19 compared to 2016-17). As a result, all subsequent
analyses were adjusted for season and calendar time.
Our analysis found that site, FEV1 Z-score, baseline CD4 cell count,
HIV VL, presence of a cough and abnormal respiratory rate were asso-
ciated with the rate of AREs (Table 2, p-values <0.1) after adjusting
for age, sex, site, and baseline VL. Effects were consistent after adjust-
ing for the potential confounding effect of the identified risk factors,
with the exception of baseline cough and HIV VL. There was evidence
of a lower rate of AREs in participants in Malawi compared to those
in Zimbabwe (fully adjusted RR 0.31; 95% CI 0.13-0.73; p-value
0.003). Having an FEV1 Z-score <-2 was found to be associated with a
higher rate of AREs in the minimally adjusted model, although this
result was attenuated in model 2 (fully adjusted RR 1.79 95% CI
0.98-3.27 p-value 0.06). Having a CD4 count <200 cells/mm3 was
associated with increased risk of AREs (fully adjusted RR 2.71;
95% CI 1.27-5.76; p-value 0.008). Compared to those with a nor-
mal respiratory rate at baseline, those with an abnormal respira-
tory rate had a higher rate of AREs (fully adjusted RR 2.08 95% CI
1.10-3.95 p-value 0.02). Presence of a cough at baseline was asso-
ciated with higher rates of ARE in minimally adjusted analysis
(model 1), but this association was attenuated in the fully
adjusted model indicating confounding (fully adjusted RR 1.26
95% CI 0.56- 2.84 p-value 0.58) (Table 2).Stratum-specific ARE rates varied by trial arm and risk factor.
However, statistical testing did not indicate heterogeneity in the
effect of azithromycin versus placebo in the rate of ARE for risk fac-
tors measured at baseline (Table 3; Figure S1-S6). There was weak
evidence that the effect of azithromycin versus placebo differed by
sex (LRT test for interaction= 0.07), with a reduced rate of AREs with
azithromycin treatment compared to placebo among males (RR 0.23
95% CI 0.08-0.66) but not among females (RR 0.77 95% CI 0.35-1.68).
Lower rates of AREs with azithromycin treatment compared to pla-
cebo were found among those with a cough and an abnormal respira-
tory rate, compared to those without these symptoms, those on 1st
line versus 2nd line ART, those without carriage of azithromycin resis-
tant bacteria, and those with better baseline lung function (FEV1 Z-
score -2 vs <-2). However these findings did not reach statistical
significance (Table 3).
4. Discussion
In this post hoc analysis of the BREATHE trial, we reported CD4
count <200 cells/mm3 and an abnormal respiratory rate at baseline
were risk factors for AREs, with a two-fold higher rate of AREs among
those with tachypnoea. Other studies have found tachypnoea to be
strongly associated with HIV-associated CLD in children: a cross-sec-
tional study from South Africa in 2005-2006 in children with HIV-
associated CLD found that tachypnoea was associated with reduced
FEV1, although their cohort was younger (mean age 5 years) and the
predominant pathology was LIP, which is uncommon in the ART era
[11]. An abnormal respiratory rate represents more severe CLD,
which can in turn put patients at higher risk of respiratory exacerba-
tions.
Advanced immunosuppression (i.e. aCD4 count <200 cells/mm3)
was associated with a higher risk of AREs. This is a well-recognised
factor for risk of infections including respiratory infections among
individuals living with HIV [12]. We observed seasonal variation of
respiratory illnesses, with ARIs being more common during the
colder dry season in Zimbabwe [13]. This finding, also documented in
Table 2
Risk factors for AREs.
Variable categories Total episodes of AREs/100 person-years Model 1 RR (95% CI) [1] p-value[2] Model 2 RR[3] (95% CI) p-value[2]
Total 57/309
Age (years) 6-15 30/182 1 0.90 1 0.25
16+ 27/127 0.96 (0.53-1.76) 0.69 (0.37-1.31)
Sex Male 25/161 1 0.25 1 0.47
Female 32/148 1.41 (0.78-2.53) 1.29 (0.72-2.29)
Site Zimbabwe 50/216 1 0.005 1 0.003
Malawi 7/93 0.33 (0.14-0.77) 0.31 (0.13-0.73)
FEV1 Z-score -2 21/168 1 0.03 1 0.06
<-2 36/141 2.18 (1.16-4.10) 1.79 (0.98-3.27)
CD4 count
(cells/mm3)
 200 43/279 1 0.006 1 0.008
<200 14/30 3.00 (1.42-6.40) 2.71 (1.27-5.76)
HIV VL
(copies/ml)
<1000 25/176 1 0.09 1 0.50
1000 32/133 1.67 (0.93-3.00) 1.30(0.70-2.47)
ART line 1st 35/233 1 0.16 1 0.46
2nd 22/76 1.59 (0.84-3.01) 0.90 (0.44-1.88)
Weight for age Z-score Not underweight 29/144 1 0.82 1 0.91
Underweight 28/165 1.08 (0.57-2.04) 0.97 (0.52-1.79)
Height for age Z-score Not stunted 26/157 1 0.70 1 0.99
Stunted 31/152 0.89 (0.48-1.64) 1.00 (0.55-1.82)
Presence of a cough No 45/282 1 0.04 1 0.58
Yes 12/27 2.36 (1.07-5.19) <
Abnormal RR No 21/174 1 0.02 1 0.02
Yes 36/135 2.19 (1.14- 4.19) 2.08 (1.10- 3.95)
History of TB No 36/219 1 0.68 1 0.92
Yes 21/89 1.15 (0.61-2.17) 0.97 (0.53-1.78)
Season Rainy 21/156 1 0.06 1 0.12
Dry 36/153 1.67 (0.97-2.86) 1.67 (0.98-2.87)
Calendar Period (years) 2016-2017 35/121 1 0.004 1 0.05
2018-2019 22/188 0.44 (0.25-0.77) 0.49 (0.28-0.89)
1adjusted for trial arm, age, sex, site, season, calendar time, and HIV VL (continuous)
2p-value from LRT
3adjusted for trial arm, age, sex, site and season, calendar time, HIV VL (continuous), abnormal RR, cough, CD4 count and FEV1 Z-score.
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including respiratory syncytial virus, which shows peak activity in
June, July and August in Southern Africa and is one of the commonest
causes of ARIs, both in SSA and globally [14]. Being recruited from
Zimbabwe, compared to Malawi was also found to be a risk factor for
AREs. There is no clear explanation for this. Possible reasons include
differences in demographics or reporting. Poverty and the multiple
associated risk factors have long been associated with lower respira-
tory tract infections [15]. According to the World Bank Poverty and
Equity report, Zimbabwe has higher rates of national poverty at 70%
compared to a national poverty rate of 51.5% in Malawi. The situation
in Zimbabwe is also compounded by recent droughts and a deterio-
rating economic situation, which has made food security and health
service delivery increasingly fragile [16], all of which may contribute
to increased rates of AREs.
The BREATHE trial found that rates of total AREs were approxi-
mately 50% lower in the group who received weekly weight based
dosing of azithromycin compared to the placebo group, and this asso-
ciation remained after adjusting for a priori determined factors [5]. In
addition to trial arm, this post hoc analysis found that the crude rates
of AREs differed by age, sex, site, FEV1 Z-score, CD4 count, HIV VL,
being on second line ART, history of TB treatment, resistance to azi-
thromycin at baseline, season and calendar year. Our findings show
that azithromycin reduced AREs in participants with a baseline FEV1
Z-score -2, (RR 0.25 95%CI 0.08-0.77). This result may also be related
to previous AREs, and in turn possible baseline antibiotic resistance. A
prospective cohort study from South Africa by Githinji et al found that
amongst adolescents with HIV a lower FEV1 score was associated
with previous lower respiratory tract infections [17]. These individu-
als may hence have had more frequent treatment with previous
courses of antibiotics, possibly increasing the presence of baseline
antibiotic resistance, making prophylactic azithromycin less effectivein this subgroup. We also found azithromycin reduced AREs in partic-
ipants with an abnormal respiratory rate, representing symptomatic
CLD and a group who are more likely to experience recurrent AREs.
These participants may hence benefit more from preventative weekly
treatment with azithromycin. We also found variation in the effect of
azithromycin with regards to resistance to azithromycin at baseline,
but the test for interaction did not reach statistical significance (likely
due to low statistical power); stratum specific rate ratios suggested
increased rates of ARE among those resistant to azithromycin and
reduced rates of ARE among those without azithromycin resistance
at baseline (RR 1.38 95% CI 0.19-9.93 and RR 0.42 95% CI 0.22-0.81
respectively).
Azithromycin appeared to reduce AREs by 77% in males but only
23% in females (stratum specific RR in the azithromycin group was
0.23 and 0.77 respectively). One possible explanation for variation by
sex, is engagement with care. In this cohort most participants were
older adolescents and so would likely take responsibility themselves
for accessing care. Being male and under the age of 30 is a risk factor
for disengaging from HIV care [18] and HIV related mortality in SSA
is higher in males for this reason [19]. In this cohort male adolescents
may be less likely to seek acute care for AREs, or may only seek care
with severe symptoms, resulting in an increased likelihood of
experiencing AREs in the future. As a result preventative treatment
may have a greater impact in this subgroup.
Notably, azithromycin is well tolerated, and has no significant
interactions with commonly used ART [20]. The BREATHE trial
reported that the number of adverse events was higher in the placebo
arm than the azithromycin arm and only reported minor gastrointes-
tinal side effects [5]. Prevention of AREs in this population is likely to
have benefits that extend beyond reducing symptoms. AREs are
linked to worsening FEV1 in both children and adults with cystic
fibrosis [21], and in children with non-cystic fibrosis bronchiectasis
Table 3
Rates of ARE stratified by arm and explanatory variables and stratum specific estimates of effect of azithromycin on total episodes of AREs.
Explanatory variable Placebo arm Azithromycin arm
Total episodes of
AREs 1













Total 38/ 154 24.66 (17.29-36.44) 19/155 12.27 (7.42-21.83) 0.50 (0.29-0.87)
Age (years) 6-15 17/82 20.79 (12.00-39.39) 13/100 12.93 (6.92-27.10) 0.60 (0.27-1.33) 0.4
16+ 21/72 29.0 (18.23-49.17) 6/54 11.04 (4.51-34.61) 0.35 (0.13-0.94)
Sex Male 20/76 26.44 (16.37-45.64) 5/85 5.88 (2.55-16.88) 0.23 (0.08-0.66) 0.07
Female 18/78 22.95 (13.50-42.28) 14/70 20.04 (10.90-41.08) 0.77 (0.35-1.68)
Site Zimbabwe 33/107 30.78 (21.11-46.70) 17/108 15.68 (9.17-29.18) 0.49 (0.25-0.93) 0.85
Malawi 5/47 10.67 (3.80-41.84) 2/47 4.30 (0.96-40.09) 0.41 (0.07-2.24)
FEV1 Z-score -2 17/84 20.21 (11.28-39.96) 4/84 4.79 (1.85-16.53) 0.25 (0.08-0.77) 0.17
<-2 21/70 30.01 (19.41-49.03) 15/71 21.04 (11.82-41.29) 0.62 (0.30-1.30)
CD4 count (cells/
mm3)
<200 9/16 57.01 (25.75-
151.80)
5/15 34.37 (7.68-321.78) 0.53 (0.14-1.98) 0.84
200 29/138 20.97 (14.16-32.44) 14/140 9.98 (6.16-17.28) 0.46 (0.23-0.90)
HIV VL (copies/ml) <1000 16/83 19.22 (11.05-36.58) 9/92 9.73 (5.33-19.82) 0.49 (0.21-1.14) 0.98
1000 22/71 31.06 (19.54-52.45) 10/62 16.02 (7.18-43.44) 0.50 (0.21-1.16)
ART line 1st 26/119 21.78 (13.95-36.02) 9/113 7.95 (4.00-18.20) 0.35 (0.16-0.79) 0.32
2nd 12/35 34.56 (19.42-67.44) 10/42 24.00 (11.49-58.94) 0.67 (0.25-1.77)
Weight for age Z-
score
Underweight 18/75 24.04 (14.53-42.80) 10/90 11.09 (6.29-21.51) 0.44 (0.19-1.03) 0.81
Not underweight 20/79 25.25 (15.27-44.90) 9/65 13.90 (5.76-42.62) 0.51 (0.21-1.22)
Height for age Z-
score
Stunted 16/72 22.30 (12.85-42.27) 10/86 11.68 (6.64-22.60) 0.49 (0.21- 1.17) 0.89
Not stunted 22/82 26.72 (16.75-45.36) 9/69 12.99 (5.37-39.95) 0.45 (0.19-1.06)
Presence of a cough No 28/139 20.16 (13.16-32.53) 17/143 11.92(7.09-21.68) 0.55 (0.29- 1.06) 0.2
Yes 10/15 65.67 (37.38-
126.21)
2/12 16.38 (4.10-65.50) 0.30 (0.06-1.68)
Abnormal RR No 10/79 12.66 (6.74-26.75) 11/95 11.55 (5.67-26.75) 0.81 (0.33-2.01) 0.19
Yes 28/75 37.30 (24.59-59.40) 8/60 13.42 (6.50-32.48) 0.35 (0.15-0.82)
History of TB
treatment
No 27/119 22.74 (14.73-37.04) 9/101 8.94 (4.51-20.39) 0.42 (0.19-0.95) 0.71
Yes 11/35 31.12 (16.92-63.72) 10/53 18.77 (8.88-46.93) 0.55 (0.20-1.44)
Resistance to AZM
at baseline
No 36/137 26.35 (18.25-39.49) 16/142 11.29 (6.56-21.17) 0.42 (0.22-0.81) 0.26
Yes 2/17 11.47 (2.75-94.52) 3/13 22.82 (4.41-280.93) 1.38 (0.19-9.93)
Season Rainy 13/78 16.72 (9.68-31.56) 8/78 10.26 (5.33-22.48) 0.58 (0.23-1.45) 0.58
Dry 25/76 32.75 (22.00-51.02) 11/77 14.30 (7.78-29.36) 0.42 (0.20-0.89)
Calendar Period
(years)
2016-2017 23/59 39.00 (26.66-59.29) 12/62 19.30 (10.03-42.25) 0.48 (0.22-1.05) 0.95
2018-2019 15/95 15.78 (8.52-32.74) 7/95 7.40 (3.28-20.46) 0.46 (0.18-1.20)
1events/ total person years
2per 100 person years
3adjusted for age (categorized as 6-10, 11-15 and 16+), sex, site, season, calendar time and HIV VL
4p-value from LRT.
6 A. Price et al. / EClinicalMedicine 42 (2021) 101195pulmonary exacerbations are the main risk factor for a decline in
FEV1 [22]. Prevention of AREs may hence protect against further
decline in lung function. It is also important to consider the psychoso-
cial impact of AREs. A cross sectional study in children with cystic
fibrosis in the US found that children reporting an ARE in the previ-
ous 6 months had worse psychosocial scores on the child health
questionnaire compared to those without a recent ARE, indicating
that the impact of AREs goes beyond pure physical symptoms [23].
Frequent AREs also impact schooling due to missed school days. A
study from Zimbabwe showed that children and adolescents with
HIV miss more school days and are more likely to repeat a school
year compared to their HIV negative peers [24]. This likely has a sig-
nificant impact on educational attainment, hence any means of
reducing this disparity should be a priority. However, when consider-
ing prophylactic use of azithromycin resistance is a key concern, and
previous studies have shown emergence of resistance associated
with use of azithromycin. A study investigating the effect of weekly
azithromycin in indigenous children with non-cystic fibrosis bronchi-
ectasis in Australia and New Zealand reported antibiotic resistance to
be seven times higher in the treatment group compared to the pla-
cebo group [25]. A Cochrane systematic review on the use ofmacrolides in patients with cystic fibrosis found that 2 of the 10
included studies reported a significant increase in macrolide resistant
strains of Staphylococcus aureus in patients receiving azithromycin
[26]. This will not only remove the benefit of prophylactic azithromy-
cin in this population, but is also an important public health concern.
To date no other studies have evaluated potential treatments for
HIV associated CLD in children and adolescents, and none have
looked at the incidence or risk factors for AREs in this population.
Strengths of this study include its robust design: as a double blinded
randomized placebo-controlled control trial it is best placed to evalu-
ate the impact of azithromycin on ARE in this cohort, minimizing
confounding and many potential sources of bias. However, this study
also has important limitations. The definition of ARE was a clinical
one and there may have been differences in ascertainment by trial
site. However, a clinical definition was selected as a pragmatic
approach as microbiological tests are often not available in these set-
tings. The impact of azithromycin on AREs was a secondary outcome
and the BREATHE trial was not powered for this outcome, as a result
our findings provide a basis for further research rather than firm evi-
dence. Additionally, residual confounding may still exist, for example
this study did not examine smoking status, something which may be
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ever, smoking was not considered by the trial group because of the
negligible prevalence of smoking in this group reported in other
studies [27,28]. This study also examined for a total of 14 risk factors
and we acknowledge the limitations of multiple testing. [29]. Lastly
this study focused on subgroup analyses and examined for effect
modification using a statistical test for interaction. Tests for interac-
tion are frequently underpowered and have known limitations [30].
As a result there is a risk we may have failed to detect effect modifica-
tion where it does exist, and these results require cautious interpreta-
tion.
In summary, risk factors for AREs in this population included pres-
ence of an abnormal respiratory rate at baseline and having a baseline
CD4 count <200/mm3. Azithromycin was effective at reducing AREs
in male participants but there was no evidence among female partici-
pants. There was no statistical evidence for effect modification over-
all, however in stratified analyses there was evidence of
azithromycin having a greater impact on reducing AREs in partici-
pants with chronic respiratory symptoms at baseline, those on 1st
line ART, those with a FEV1 score >-2 and participants without base-
line resistance to azithromycin. This exploratory analysis has
highlighted potential subgroups who may benefit the most from
treatment with weekly azithromycin, although further evidence is
required. The use of targeted treatment may reduce concerns regard-
ing the emergence of AMR, and children and adolescents with HIV-
associated CLD should be screened for these respiratory symptoms
and clinical characteristics to help identify those most at risk of AREs
and to guide management.
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